ValiRx plc reiterated earnings guidance for the year2024. Valmet reiterates its guidance issued on February 7, 2024, in which Valmet estimates that net sales in 2024 will remain at the previous year's level in comparison with 2023 (EUR 5,532 million).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.6 GBX | -1.89% | -8.77% | -55.93% |
May. 20 | London gets boost thanks to rate cut hopes | AN |
May. 20 | ValiRx shares jump as Cytolytix gets Knowledge Transfer Voucher grant | AN |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-55.93% | 4.36M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- VAL Stock
- News ValiRx plc
- Valirx plc Reiterates Earnings Guidance for the Year 2024